Skip to main content
SpringerLink
Log in

Cytokine associated renal dysfunction: Interleukins and interferons

  • Chapter
Clinical Nephrotoxins

  • 332 Accesses

Abstract

Kidney function can be adversely affected by various cytokines. Cytokine associated renal dysfunction is regularly observed in the setting of sepsis syndrome. However, in this setting it is difficult to isolate direct nephrotoxic effects of individual cytokines among the cascade of mediators which produce the syndrome of shock and hypotension.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Belldegrun A, Webb D, Austin H, Steinberg S, White D, Lineham W, Rosenberg S. Effects of Interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987; 106: 817–22.

    Article  PubMed  CAS  Google Scholar 

  2. Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S, Linehan W, Robertson C, Lee R, Rubin J, Seipp C, Simpson C, White D. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 888–97.

    Google Scholar 

  3. Lotze M, Matory Y, Rayner A, Ettinghausen S, Vetto J, Seipp C, Rosenberg S. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764–72.

    Article  PubMed  CAS  Google Scholar 

  4. Margolin K, Rayner A, Hawkins M, Atkins M, Dutcher J, Fisher R, Weiss G, Doroshow J, Jaffe H, Roper M, Parkinson D, Wiernik P, Creekmore S, Boldt D. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Onc 1989; 7: 486–98.

    CAS  Google Scholar 

  5. Rosenstein M, Ettinghausen S, Rosenberg S. Extravasation of intravascular fluid mediated by the stemic administration of recombinant interleukin 2. J Immunology 1986; 137:1735–42.

    CAS  Google Scholar 

  6. Schomburg A, Kirchner H, Atzpodien J. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy. J Cancer Res Clin Oncol 1993; 119(12): 745–55.

    Article  PubMed  CAS  Google Scholar 

  7. Demchak P, Mier J, Robert N, O’Brien K, Gould J, Atkins M. Interleukin-2 and high-dose Cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991; 9(10): 1821–30.

    PubMed  CAS  Google Scholar 

  8. Textor S, Margolin K, Blayney D, Carlson J, Doroshow J. Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man. Am J Med 1987; 83: 1055–61.

    Article  PubMed  CAS  Google Scholar 

  9. Christiansen N, Skubitz K, Nath k, Ochoa A, Kennedy B. Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2. Am J Med 1988; 84; 1072–5.

    Article  PubMed  CAS  Google Scholar 

  10. Kozeny G, Nicholas J, Creekmore S, Sticklin L, Hano J, Fisher R. Effects of interleukin-2 immunotherapy on renal function. J Clin Onc 1988; 6(7): 1170–6.

    CAS  Google Scholar 

  11. Shalmi C, Dutcher J, Feinfeld D, Chun K, Saleemi K, Freeman L, Lynn R, Wiernik P. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. J Clin Onc 1990; 8(11): 1839–46.

    CAS  Google Scholar 

  12. Hall T, James P, Cambridge G. Interleukin-2 nephrotoxicity assessed in vitro. Res Comm Chem Path Pharm 1991; 73(3): 375–8.

    CAS  Google Scholar 

  13. Gutterman J, Fine S, Quesada J, Horning S, Levine J, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96(5): 549–56.

    Article  PubMed  CAS  Google Scholar 

  14. Quesada J, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman J. Collaborative Phase I-II study of recombinant DNA-pro-duced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med 1984; 77: 427–32.

    Article  PubMed  CAS  Google Scholar 

  15. Crockett D, Lusk R, McCabe B, Mixon J. Side effects and toxicity of interferon in the treatment of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 1987; 96: 601–7.

    PubMed  CAS  Google Scholar 

  16. Abdulhay G, DiSaia P, Blessing J, Creasman W. Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a gynecologic oncology group study. Am J Obstet Gynecol 1985; 152: 418–23.

    PubMed  CAS  Google Scholar 

  17. Sherwin S, Knost J, Fein S. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 1982; 248: 2461–6.

    Article  PubMed  CAS  Google Scholar 

  18. Quesada J, Talpaz M, Rios A, Kurzrock R, Gutterman J. Clinical toxicity of interferons in cancer patients: a review. J Clin Onc 1986; 4(2): 234–43.

    CAS  Google Scholar 

  19. Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, Liberati A, Gerli R, Greco F, Moretti A, Monti M, Gentilini P, Bombardieri S, Zignego A. Interferon-αin mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81(5): 1132–6.

    PubMed  CAS  Google Scholar 

  20. Averbuch S, Austin H, Sherwin S, Antonovych T, Bunn P, Longo D. N Engl J Med 1984; 310(1): 32–5.

    Article  PubMed  CAS  Google Scholar 

  21. Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. Brit Med J 1985; 290: 1180–1.

    Article  CAS  Google Scholar 

  22. Herrman J, Gabriel F. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon. N Engl J Med 1987; 316(2): 112–3.

    Article  PubMed  CAS  Google Scholar 

  23. Gresser I, Maury C, Tovey M. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 1976; 263: 420–2.

    Article  PubMed  CAS  Google Scholar 

  24. Morel-Maroger L, Sloper J, Vinter J, Woodrow D, Gresser I. An ultrastructural study of the development of nephritis in mice treated with interferon in the neonatal period. Lab Invest 1978; 39: 513–22.

    PubMed  CAS  Google Scholar 

  25. Schiller J, Storer B, Willson J, Borden E. Phase I trial of combinations of recombinant interferons beta and gamma in patients with advanced malignancy. Cancer Treat Rep 1987; 71(10): 945–52.

    PubMed  CAS  Google Scholar 

  26. Schiller J, Storer B, Witt P, Nelson B, Brown R, Horisberger M, Grossberg S, Borden E. Biological and clinical effects of the combination of beta and gamma interferons administered as a 5 day continuous infusion. Cancer Res 1990; 50: 4588–94.

    PubMed  CAS  Google Scholar 

  27. Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, Bonnern EM, Fefer A. Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunotherapy 1987; 25: 47–53.

    Article  CAS  Google Scholar 

  28. Sridkandan K, Garner P, Watkinson K, Pettingale K, Brinkley D, Caiman F, Tee D. A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer. Cancer Chemother Pharmacol 1986; 18: 63–8.

    Article  Google Scholar 

  29. Ault B, Stapleton F, Gaber L, Martin A, Roy S, Murphy S. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988; 319(21): 1397–400.

    Article  PubMed  CAS  Google Scholar 

  30. Memoli B, De Nicola L, Libetta C, Scialo A, Pacchiano G, Romano P, Palmieri G, Morabito A, Lauria R, Conte G et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. Amer J Kidney Dis 1995; 26(1): 27–33.

    Article  CAS  Google Scholar 

  31. Ponce P, Cruz J, Travassos J, Moreira P, Oliveira J, Melo-Gomes E, Gouveia J. Renal toxicity mediated by continuous infusion of recombinant interleukin-2. Nephron 1993; 64(1) 114–8.

    Article  PubMed  CAS  Google Scholar 

  32. Horowitz R, Glicklich D, Sablay LB, Wiernik PH, Wadler S. Interferon-induced acute renal failure: a case report and literature review. Med Onc 1995 (Mar); 12(1): 55–7.

    Article  CAS  Google Scholar 

  33. Miranda-Guardiola F, Fernandez-Llama P, Badia JR, Botey A, Estruch R, Darnell A, Rozman C, Revert L. Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B. Nephrology, Dialysis, Transplantation 1995; 10(8): 1441–3.

    CAS  Google Scholar 

  34. Rostaing L, Modesto A, Baron E, Cisterne JM, Chaban-nier MH, Tkaczuk J, Durand D, Suc JM. Acute renal insufficiency in renal transplants treated with interferon-alpha for chronic hepatitis C (Original title: Insuffisance renale aigue chez des transplantes renaus traites par interferon-alpha pour une hepatite chronique C. Nephrologie 1996; 17(4): 247–54.

    PubMed  CAS  Google Scholar 

  35. Vlasveld LT, van de Wiel-van Kemenade E, de Boer AJ, Sein JJ, Gallee MP, Krediet RT, Mellief CJ, Rankin EM, Hekman A, Figdor CG. Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer. Canc Immunology, Immunotherapy 1993; 36(3): 210–3.

    Article  CAS  Google Scholar 

  36. Coroneos E, Petrusevska G, Vaarghese F, Truong LD. Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Amer J Kidney Dis 1996 (Dec); 28(6): 888–92.

    Article  CAS  Google Scholar 

  37. Dhib M, Bakhache E, Postec E, Vanrenterghem B, Le Roy F, Azar R, Francois A, Boldron A, Amaria R, Ozenne G, Hermelin A. Nephrotic syndrome complicating treatment with interferon alpha (Original title: Syndrome nephrotique compliquant un traitement par interferon alpha). Presse Medicale 1996 (June 29); 25(23): 1066–8.

    CAS  Google Scholar 

Download references

Authors
  1. Mary M. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Nephrology and Hypertension, University of Antwerp, Belgium

    M. E. De Broe  & G. A. Verpooten  & 

  2. Department of Medicine, The Oregon Health Sciences University, Portland, Oregon, 97201, USA

    G. A. Porter

  3. Division of Nephrology, The Oregon Health Sciences University, Portland, Oregon, 97201, USA

    W. M. Bennett

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Meyer, M.M. (1998). Cytokine associated renal dysfunction: Interleukins and interferons. In: De Broe, M.E., Porter, G.A., Bennett, W.M., Verpooten, G.A. (eds) Clinical Nephrotoxins. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9088-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9088-4_23

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-015-9090-7

  • Online ISBN: 978-94-015-9088-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation